Italy. The venue was wonderful and the program was outstanding. This years meeting will undoubtably be remembered as among the best organized and most enjoyable of the many successful p53 meetings.
It was apparent from this years meeting that even after 20 years, the ®eld is far from maturing and is actually accelerating. There were many fascinating and important presentations at this years meeting, some of which are discussed below as are some of the more practical discussions with respect to future therapeutic approaches.
There has been a developing consensus over the past 2 years that there are two major pathways to activate p53. These include activation through genotoxic stress or through oncogene expression. Both pathways result in the disruption of MDM-mediated p53 degradation resulting in stabilization of p53 followed by p53-mediated cell cycle arrest or apoptosis. Genotoxic stress results in the phosphorylation of p53 at the Nterminal and the C-terminal regions destabilizing the interaction between p53 and MDM. Oncogene expression, including myc, ras, and E1A, can result in activation of E2F-mediated ARF gene expression where the ARF protein can likewise inhibit MDMmediated p53 degradation. However, based on some of the presentations, the above may be an oversimplification. For example, Geof Wahl presented data showing that oncogene expression, including myc, also gives rise to DNA damage. This is consistent with previous studies and it will now be important to determine how myc induces DNA damage. In addition, DNA damage can also result in induction of ARF gene expression. It was suggested that there may be a temporal regulation of p53 where dierent mechanisms are not mutually exclusive. For example, genotoxic stress may induce a more rapid activation of p53 through phosphorylation and that a more long term stabilization of p53 following genotoxic stress may be mediated through ARF expression.
David Lane presented his observations that phosphorylation of p53 following DNA damage may not be the major pathway in which p53 is stabilized following genotoxic stress. He revealed that the level of MDM can be signi®cantly reduced following genotoxic stress and this could play a major role in activating p53 following DNA damage. This observation is consistent with a recent report that mutation of all phosphorylation sites of p53 did not signi®cantly inhibit the ability of DNA damage to activate p53 activity (see subsequent review by K Vousden). This is also consistent with the fact that mutations in the p53 phosphorylation sites are not observed in tumours. It is possible that there is redundancy in the way in which p53 can become activated following genotoxic stress and that phosphorylation although not entirely necessary, can nevertheless activate the p53 response.
Bill Kaelin discussed his recent observations with respect to the interactions between p53 and its homologs p73-a and p73-b. It was previously established that the p53 homologs p73 and p63 were able to transactivate p53 responsive elements and induce cell cycle arrest and apoptosis. However, available evidence suggests that p73 and p63 do not become activated following DNA damage. Moreover, there is no evidence to date that the p73 and p63 genes become mutated in cancers, further arguing that these are not tumor suppressor genes. However, a link has been established between p53 and p73 since it was shown that certain mutant forms of p53 can bind to and inactivate p73. What was striking however was that the naturally occurring polymorphism at amino acid residue 72 of p53 appears to be relevant with respect to mutant p53 molecules binding and inactivating p73. P53 occurs in two wildtype polymorphic variants within the general populations where amino acid residue 72 can be either arginine (p53Arg) or proline (p53Pro). It was shown that the p53Arg variant when mutated had a higher anity for p73 than mutant forms of the p53Pro variant. Interestingly, mutant p53Arg variants also had higher anity for p73 than did the wildtype p53Arg variants. This suggests that mutations in the p53Arg variant may have a greater gain of function activity than mutations in the p53Pro variant with respect to inhibiting p73 activity. This was interesting in light of the observation presented by Bill Kaelin, that in skin cancer, the p54Arg variant gene becomes mutated to a signi®cantly greater degree than the p53Pro gene. This suggests that the p53Pro gene may be protective against skin cancer and this would *Correspondence: G Matlashewski Oncogene (1999) 18, 7618 ± 7620 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $15.00 http://www.stockton-press.co.uk/onc be consistent with the previous observation that the p53Pro gene is more common in darker skin populations living closer to the equator. Such observations are also interesting in light of a previous observation that the p53Arg variant is preferentially targeted in cervical cancers and skin cancers associated with human papillomavirus infections (see review by L Banks). An interesting hypothesis may be that the p53Pro allele is generally more protective against skin cancers than the p53Arg allele. Clearly, carefully designed molecular epidemiologic studies are needed to establish such a link between loss of the p53Arg allele either by mutation of HPV infection in the development of epithelial tumors of the skin.
Another major unresolved question is what determines whether activation of p53 results in apoptosis or cell cycle arrest. Nicholas LaThangue presented his observation that a novel p300 cofactor, JMY, was involved in regulating p53 activity. P300/CBP proteins exist as multiprotein complexes which act as coactivators for diverse transcription factors including p53. Data was presented showing that dierent splice variants of JMY may determine in part whether p53 mediates cell cycle arrest or apoptosis. It was also suggested that E2F levels could contribute to determining whether cells undergo apoptosis, since high relative levels of E2F may be a stimulator of apoptosis.
Another unresolved issue is whether tumors with wildtype p53 are more responsive to apoptosis inducing cancer therapy than tumors with mutated p53. Sam Benchimol and Fred Bunz discussed this issue with respect to their respective approaches to making isogenic lines which dier only with respect to their p53 status. It turns out that the answer is not as simple as the question. The responsiveness of these lines to chemotherapy depended on both the type of treatment as well as how the p53 alleles were removed or mutated. It was suggested by Sam Benchimol that it will be important to better understand how mutant forms of p53 may alter wildtype p53 function when attempting to understand this issue. Fred Bunz pointed out that p53 null cells were more sensitive to DNA damaging agents, but had a decreased sensitivity to 5-uorouracil. The point was raised by Arnold Levine that more collobarative eorts are needed between clinicians and scientists to carefully address the issue regarding therapy response and p53 status of the tumors.
The speci®city of the p53 promoter has not been satisfactorily understood. The consensus binding sequence appears to be relatively non-stringent for a transcription factor with such profound biological eects. Wolfgang Deppert has provided further insight into this issue through presenting his observations that sequence conformation may provide additional speci®city over primary sequence alone. He suggested that conformation based on chromatin structure may provide greater speci®city for p53 target genes.
Overall, among the most satisfactory advances discussed at this years meeting has been the deeper appreciation for the regulation of MDM-mediated p53 degradation. In particular, Karen Vousden and Gordon Peters provided additional insight how p53 levels can be controlled by ARF through its ability to bind and impair MDM-mediated p53 degradation.
ARF levels can be upregulated by E2F as a potential fail-safe mechanism to protect from uncontrolled cell proliferation. Therefore, mutations in ARF results in downmodulation of p53 through uncontrolled MDMmediated degradation. Karen Vousden also presented data showing that increased E2F activity can increase cells sensitivity to TNF-mediated apoptosis. What is perhaps most signi®cant is that many tumors with wildtype p53 have suered mutations in the ARF gene or display over expression of MDM, and therefore these tumors are functionally impaired with respect to activation of p53. Consequently, the majority of all cancer cells have suered either a mutation in the p53 gene or alterations in genes encoding p53 regulatory molecules such as MDM or ARF. Disruption of the normal p53, MDM, and ARF complex is therefore arguably the most pivotal and consistent molecular event in cancer cell development. As noted below, this complex represents an important target for the development of new cancer therapies.
The next twenty years p53 can be considered natures inherent defense against cancer. Tremendous progress is underway in de®ning how and why it works, some of which is described above. Consequently, well within the next 10 years, treatments will be developed based on the knowledge and understanding of the p53 pathways. Some of the presentations at this years meeting provided ®rm justi®cation for these high future expectations.
Perhaps the most imminent treatment to result from the understanding of p53 is the work discussed by Frank McCormick regarding the Adenovirus defective in the E1B 55K gene, the Onyx015 virus. Because this virus is defective in the E1B 55K gene, it is unable to inhibit wildtype p53 in the infected cell. Consequently, Onyx015 is unable to multiply in normal cells due to the p53-dependent apoptotic response. However, Onyx015 is able to multiply in cells with mutated p53 genes resulting in completion of its lytic life cycle killing the infected tumor cells. One of the puzzling issues with this mutant virus was that it was also able to multiply in some tumor cell lines which retained wildtype p53 genes. However, as discussed above, it is now appreciated that the ARF gene is often mutated in wildtype p53 containing tumors and thus the wildtype p53 cannot be activated following virus infection. This therefore provided a satisfactory explanation why the Onyx015 could multiply in some wildtype p53 containing tumors. More importantly, this suggests that Onyx015 may be eective on a wider range of tumors to include those tumors which have wildtype p53 but defects upstream of p53 such as ARF mutations or MDM overexpression.
Most striking however has been the clinical data obtained with the Onyx015 in the treatment of head and neck cancers which have not responded to standard chemotherapy or radiotherapy. The Onyx015 virus was shown to be safe and eective in the majority of the patients treated. There was no indication that the virus could replicate in normal noncancerous cells. Interestingly, Onyx015 treated tumors showed an in®ltration of macrophages and neutrophils which likely synergized with the lytic eects of the virus p53: Twenty years on G Matlashewski to cause tumor regression. One explanation for the failure of some tumors to respond was that they were too physically solid to inject eectively with the virus preparation. Overall, the meeting participants were impressed with this elegant approach to cancer therapy.
Arnold Levine presented results using microarray technology to determine how many genes are eected by the p53 protein in the absence of DNA damage. Some 70 genes went induced and 80 suppressed following induction of p53 expression, and equally impressive, there was considerable variation with respect to the kinetics of expression. Ultimately, this approach holds promise for identifying major p53 targets with therapeutic potential.
David Lane discussed several relevant issues concerning potential new p53 based cancer treatments. First, it was pointed out how speci®c the antip53 antibodies are for tumors with mutant p53. p53 is readily and speci®cally detected in these cancer cells because it is defective and thus there is no MDM feedback mechanism to down modulate p53 levels. This provides a vivid appreciation that abnormally high p53 levels represents a clear marker for cancer which can be exploited through de®ning its regulation and function. Cancers fall into two categories, those with wildtype p53 and those with mutant p53. It was pointed out that mutant p53 containing tumors could be targeted in a variety of ways including the Onyx015 virus discussed above, gene therapy including p53 genes and p53 downstream genes, and peptides which can re-awaken mutant p53 protein function. The peptide approach was elaborated on at the meeting by Galina Selivanova who showed her latest results with a p53 C-terminal derived peptide containing residues 361 ± 382. This peptide binds the core domain of partially unfolded p53 characteristic of mutant p53 with higher anity than to wildtype p53. The 361 ± 382 peptide could stimulate p53 sequence speci®c DNA binding of ®ve dierent common p53 mutants.
Moreover, this peptide can induce apoptosis in mutant p53 containing tumor cell lines. This argues that common mutant p53 proteins can be`re-awakened' under appropriate conditions. Several relevant issues concerning the treatment of wildype p53 containing cancer cells were also pointed out by David Lane. For example, agents could be developed to disrupt the p53/MDM interaction or mimic ARF activity. Appropriate peptides may be able to carry out these functions. Ideally, however, small molecules would be better than peptides in this regard because of stability and versatility. It was also pointed out that targeting MDM/p53 in such tumors may be preferable to treatment with dangerous genotoxic agents which could result in future tumor developments.
A number of tumors are characterized with an overactive export of p53 out of the nucleus such as for example neuroblastomas. As a result, p53 is essentially non-functional in these cells. Both David Lane and Arnold Levine presented data using a small molecule, leptomycin, which inhibits the export of p53 out of the nucleus in neuroblastoma cells. The result was an increase in p53-dependent transcription resulting in a p53-dependent apoptosis. Equally signi®cant, addition of leptomycin to normal primary human ®broblasts induced cell cycle arrest, but the cells were able to recover and did not undergo apoptosis. This provides evidence that activation of p53 is more lethal to cancer cells with respect to inducing apoptosis than to normal cells.
The overall message from this years meeting was that it is becoming more evident how p53 functions as a tumor suppressor and this is providing ample opportunity to exploit the p53 pathways for new therapies.
I apologize to colleagues whose work was not highlighted due to space limitations or oversight. I also wish to acknowledge the support of the National Cancer Institute of Canada.
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